CLNN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLNN is not a good buy right now for a beginner, long-term investor, even with $50,000-$100,000 available. The stock has some short-term strength, but the overall setup is not strong enough to justify an immediate buy. I would not call it a clear buy today; the better decision is to hold off until the trend and fundamentals improve.
The current price is 6.45, above the previous close of 6.16, showing a positive daily move of 6.21%. However, the trend is still mixed to bearish overall. MACD histogram is negative at -0.0654, though it is contracting, which suggests downside momentum is easing. RSI_6 at 53.91 is neutral and does not confirm a strong breakout. Moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, which means the longer-term trend is still weak. Price is sitting near the pivot level of 6.149, with resistance at 6.921 and support at 5.378. The recent pattern estimate suggests only modest near-term upside, not a strong trend reversal.
["Shares closed stronger on the day, up 6.21%, which shows some near-term buying interest.", "MACD downside pressure is weakening as the histogram is negatively contracting.", "No recent news means there is no fresh negative event-driven catalyst at the moment.", "Analyst, hedge fund, and insider activity are all neutral, so there is no major negative positioning signal."]
["Revenue in 2025/Q3 fell sharply to 15,000, down 82.76% YoY, showing severe top-line weakness.", "EPS dropped to -0.85, down 30.33% YoY, and net income remained deeply negative at -8.777 million.", "The moving average structure is bearish, with SMA_200 above SMA_20 above SMA_5.", "No recent news, no congress trading activity, and no major insider buying means there is no fresh catalyst to support a long-term re-rating.", "No AI Stock Picker signal and no recent SwingMax signal today."]
In 2025/Q3, CLNN showed weak operating performance. Revenue dropped 82.76% year over year to 15,000, which is a major deterioration in growth. Net income was still negative at -8.777 million, although the loss improved 9.90% year over year. EPS declined to -0.85, down 30.33% year over year. Gross margin was reported at 100, but given the very small revenue base, the overall financial picture remains weak and not yet supportive of a confident long-term buy.
Recent analyst activity is effectively neutral, with no meaningful trend in rating upgrades, downgrades, or target changes provided. Wall Street appears split-to-neutral rather than bullish: the pros have no clear conviction buy case here, and there is also no strong bearish consensus. With no fresh analyst momentum, the stock lacks a catalyst from the sell-side.
